Literature DB >> 34536202

Generation and characterization of a tractable C. elegans model of tauopathy.

Joshua C Russell1, Haoyi Lei2, Rahul K Chaliparambil2, Sarah Fish3, Susan M Markiewicz3, Ting-I Lee2, Anushka Noori3, Matt Kaeberlein1.   

Abstract

Alzheimer's disease(AD) is an age-associated neurodegenerative disease that results in deterioration of memory and cognitive function. As a currently untreatable disorder, AD has emerged as one of the defining biomedical challenges of our time. Thus, new approaches that can examine the cellular and molecular mechanisms underlying age-related AD pathology are sorely needed. One of the hallmarks of Alzheimer's disease is the hyperphosphorylation of the tau protein. Caenorhabditis elegans have been previously used to study the genetic pathways impacted by tau proteotoxic stress; however, currently, available C. elegans tau models express the human protein solely in neurons, which are unresponsive to global RNA interference (RNAi). This limits powerful RNAi screening methods from being utilized effectively in these disease models. Our goal was to develop a C. elegans tau model that has pronounced tau-induced disease phenotypes in cells that can be modified by feeding RNAi methods. Towards this end, we generated a novel C. elegans transgenic line with codon-optimized human 0N4R V337M tau expressed in the body wall muscle under the myo-3 promoter. Immunoblotting experiments revealed that the expressed tau is phosphorylated on epitopes canonically associated with human AD pathology. The tau line has significantly reduced health metrics, including egg laying, growth rate, paralysis, thrashing frequency, crawling speed, and lifespan. These defects are suppressed by RNAi directed against the tau mRNA. Taken together, our results suggest that this alternative tau genetic model could be a useful tool for uncovering the mechanisms that influence the hyperphosphorylation and toxicity of human tau via RNAi screening and other approaches.
© 2021. American Aging Association.

Entities:  

Keywords:  Alzheimer's disease; C. elegans; Genetic screening tool; Healthspan; Lifespan; Tauopathy

Mesh:

Substances:

Year:  2021        PMID: 34536202      PMCID: PMC8599767          DOI: 10.1007/s11357-021-00436-9

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.581


  55 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

Review 3.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 4.  [Risk factors for Alzheimer's disease].

Authors:  Tokuhei Ikeda; Masahito Yamada
Journal:  Brain Nerve       Date:  2010-07

5.  [Upper urinary tract calculi--new methods of treatment].

Authors:  P Jonas; B Morag; Z Rubinstein
Journal:  Harefuah       Date:  1985-12-15

Review 6.  Invited review: Neuropathology of tauopathies: principles and practice.

Authors:  G G Kovacs
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

Review 7.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

8.  Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease.

Authors:  Thomas J Montine; Sarah E Monsell; Thomas G Beach; Eileen H Bigio; Yunqi Bu; Nigel J Cairns; Matthew Frosch; Jonathan Henriksen; Julia Kofler; Walter A Kukull; Edward B Lee; Peter T Nelson; Aimee M Schantz; Julie A Schneider; Joshua A Sonnen; John Q Trojanowski; Harry V Vinters; Xiao-Hua Zhou; Bradley T Hyman
Journal:  Alzheimers Dement       Date:  2015-08-29       Impact factor: 21.566

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?

Authors:  John F Crary
Journal:  J Neurol Neuromedicine       Date:  2016
View more
  1 in total

Review 1.  Modeling Alzheimer's Disease in Caenorhabditis elegans.

Authors:  Javier Alvarez; Pilar Alvarez-Illera; Jaime Santo-Domingo; Rosalba I Fonteriz; Mayte Montero
Journal:  Biomedicines       Date:  2022-01-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.